Valneva SE (VALN) Cash from Investing Activities (2021 - 2026)
Valneva SE (VALN) posted Cash from Investing Activities of $321955.1 for Q1 2026, up 204.77% sequentially from -$307307.5 in Q4 2025, and up 131.85% YoY from $138863.8 in Q1 2025.
Analysis
Valneva SE (VALN) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Valneva SE has reported Cash from Investing Activities for 6 years, with the latest figure at $321955.1 in Q1 2026.
- Quarterly Cash from Investing Activities rose 131.85% year-over-year to $321955.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$525913.1 (up 95.59% YoY) and the FY2025 annual result came in at -$2.0 million, down 102.39% from the prior year.
- Cash from Investing Activities advanced to $321955.1 in Q1 2026 per VALN's latest filing, from -$307307.5 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $94.2 million in Q1 2024 and troughed at -$17.6 million in Q4 2023.
- A 5-year average of $1.7 million and a median of -$1.0 million in 2025 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 2564.61% in 2024, down 756.9% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$6.7 million in 2022, then slumped by 161.86% to -$17.6 million in 2023, then surged by 128.54% to $5.0 million in 2024, then plunged by 106.13% to -$307307.5 in 2025, then soared by 204.77% to $321955.1 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $321955.1, -$307307.5, and $230303.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 413,800.82 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 413,800.82 |
| Mar 31, 2026 | 321,955.05 |
| Dec 31, 2025 | -307,307.49 |
| Sep 30, 2025 | 230,303.85 |
| Jun 30, 2025 | -770,864.55 |
| Mar 31, 2025 | -1.01 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | -16.89 Mn |
| Jun 30, 2024 | 963,814.38 |
| Mar 31, 2024 | 94.20 Mn |
| Dec 31, 2023 | -17.56 Mn |
| Sep 30, 2023 | 7.21 Bn |
| Jun 30, 2023 | -7.22 Bn |
| Mar 31, 2023 | -3.82 Mn |
| Dec 31, 2022 | -6.70 Mn |
| Sep 30, 2022 | -6.54 Mn |
| Jun 30, 2022 | -6.99 Mn |
| Mar 31, 2022 | -10.60 Mn |
| Dec 31, 2021 | -26.60 Mn |
| Sep 30, 2021 | -35.34 Mn |